BCBéma Coulibaly

Béma Coulibaly

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Béma Coulibaly has a total of 106 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer

    by Christophe Bounaix Morand du Puch, Michelle Nouaille, Stéphanie Giraud, Anaïs Labrunie, Sandrine Luce, Pierre-Marie Preux, François Labrousse, Alain Gainant, Nicole Tubiana-Mathieu, Valérie Le Brun-Ly, et al.

    Colorectal cancer (CRC) remains a major public concern. While conventional chemotherapeutic regimens have proved useful against advanced/metastatic diseases, progresses are to be made to effectively cure the large portion of patients not benefiting from these treatments. One direction to improve response rates is to develop chemosensitivity and resistance assays (CSRAs) efficiently assisting clinicians in treatment selection process, an already long preoccupation of oncologists and researchers. Several methods have been described to this day, none achieving yet sufficient reliability for recommended use in the clinical routine. We led a pilot study on 19 metastatic CRC patients evaluating capacity of the Oncogramme, a standardized process using tumor ex vivo models, to provide chemosensitivity profiles and predict clinical outcome of patients receiving standard CRC chemotherapeutics. Oncogramme responses were categorized according to the method of percentiles to assess sensitivity, specificity and concordance. We report from a primary analysis a success rate of 97.4 %, a very good sensitivity (84.6 %), a below-average specificity (33.3 %), along with a global agreement of 63.6 % and a concordance between Oncogramme results and patients’ responses (Kappa coefficient) of 0.193. A supplementary analysis, focusing on CRC patients with no treatment switch over a longer time course, demonstrated improvement in specificity and concordance. Results establish feasibility and usefulness of the Oncogramme, prelude to a larger-scale trial. Advantages and drawbacks of the procedure are discussed, as well as the place of CSRAs within the future arsenal of methods available to clinicians to individualize treatments and improve patient prognosis. Trial registration: ClinicalTrials.gov database, registration number: NCT02305368


    • 1 January 2012
      • Vol. 133, 183-7

    [Mucoepidermoid carcinomas of salivary glands: prognostic significance of immunohistochemistry. A study of 49 cases].

    by L Santini, B Coulibaly, J Gaudart, F Turner, J Michel, A Giovanni, P Dessi, N Fakhry

    Mucoepidermoid carcinoma (MEC) is considered as the most common malignant salivary gland tumor. Its prognosis is dominated by the presence of high-grade forms involving life-threatening. The aim of our study was to evaluate the usefulness of immunohistochemistry to identify the most aggressive forms and allow better discrimination between low grade, intermediate grade and high grade tumors. This was a retrospective study of 49 cases of mucoepidermoid carcinomas of salivary glands. Two immunohistochemical markers have mainly been studied: a marker of proliferation (Ki-67) and a growth factor receptor (EGFR). Additional analyzes were performed with other markers (p53, ACE, bcl2, CD 117 and her2). Statistical analysis investigated the existence of a correlation between the presence of these factors and the histopathological grade on one hand and survival of patients on the other hand. Regarding the results of immunohistochemical Ki-67 and EGFR, it was observed a better survival rate when the immunostaining was less than 10%. The expression of Ki-67 and EGFR was correlated with the histological grade, but did not, in our study, allow discrimination between low-grade, intermediate grade and high grade. Our results are consistent with data of the literature, including Ki-67, which appears to be a useful but not powerful marker of prognosis of MEC. Other markers studied (p53, ACE, bcl2, CD 117 and her2) showed no contributory results. The prognosis of MEC is appreciated satisfactorily following histological criteria: histological grade, surgical margins, perineural invasion or vascular emboli. The integration of immunohistochemistry in a therapeutic algorithm could be particularly useful for the challenging assessment of prognosis of intermediate grades.


  • IDH mutation status impact on in vivo hypoxia biomarkers expression: New insights from a clinical, nuclear imaging, and immunohistochemical study in 34 patients with glioma.

    by P. Metellus, C. Colin, D. Taieb, E. Guedj, I. Nanni-Metellus, B. Coulibaly, C. Colavolpe, S. Fuentes, H. Dufour, M. Barrie, et al.

    2078 Background: Mutations in the gene encoding isocitrate dehydrogenase enzyme isoforms 1 (IDH1) and 2 (IDH2) have recently been identified in a large proportion of glial tumors of the CNS, but their mechanistic role in tumor development and progression remains unclear. Here, we assessed the actual impact of IDH1 and IDH2 mutations in patients harboring WHO grade 2 and 3 gliomas. Methods: We sequenced IDH1 at codon 132 and IDH2 at codon 172 in 34 patients with WHO grade 2 and 3 gliomas who benefited from a preoperative 18F-FDG positron emission tomography (PET). Immunohistochemical expression of Hypoxia Inducible Factor alpha (HIF-1 a), Carbonic Anhydrase IX (CAIX) and Glucose Transporter 1 (GLUT1) along with the R132HIDH1 mutation was assessed in all cases as well as 1p19q deletion status and p53 expression. Results: HIF-1α expression was found in 15% of IDH-mutated compared to 14.3% of IDH-nonmutated tumors (P=0.954). Also, GLUT-1 positive staining was found in 5.% of IDH-mutated and in 7.1% of IDH-nonmutated tumors (P=0.794). Finally, CA-IX expression was found in 15% of IDH-mutated and in 7.1% of IDH-nonmutated tumors (P=0.484). The combined expression of these three hypoxic markers was found in 2 WHO grade 3 tumors, one of which was IDH-mutated whereas the other was IDH-nonmutated (P=0.794). In IDH-mutated tumors, the median SUVmax ratio was 2.24 vs. 2.15 in IDH-nonmutated tumors (P=0.775). Conclusions: Together, these data suggest the absence of correlation between IDH mutation status and in vivo hypoxic biomarkers expression in WHO grade 2 and 3 gliomas.

  • Triple-negative, low-grade gliomas: A highly agressive tumor with dismal prognosis.

    by P. Metellus, B. Coulibaly, C. Colin, A. Maues de Paula, A. Barlier, A. Loundou, S. Fuentes, H. Dufour, M. Barrie, O. L. Chinot, et al.

    2023 Background: The phenotypic heterogeneity of low-grade gliomas (LGGs) is still inconsistently explained by genetic alterations characteristic in patients treated according to present standards of care. Here we investigate the combined analysis of three molecular alterations according to clinical and radiologic data in a series of 89 LGGs to provide new insights into LGGs pathogenesis. Methods: IDH1 codon 132 and IDH2 codon 172 sequencing was performed in a series of 89 LGGs and correlated with clinical presentation, MR imaging characteristics, genomic profile and outcome. Also p53 expression and 1p19q deletion status was assessed in all cases. Results: A total of 74 IDH1 mutations at codon 132 and 2 IDH2 mutations at codon 172 were found, including 68 R132H (91.9%), 4 R132C (5.4%), 2 R132S (2.7%) and 2 R172M (5%). The IDH mutations were significantly associated with 1p19q deleted genotype (P =0.027) and p53 expression (P=0.012). The presence (v absence) of IDH mutations was associated with a better outcome (5-year survival rate, 91% v 54%, respectively, P<0.001). After adjustment for age, tumor location and size, radiologic infiltration pattern and extent of surgery, multivariate analysis confirmed that IDH mutations was an independent favorable prognostic factor (hazard ratio=34.6; 95% CI, 2.72 to 329.32, P =0.006). Furthermore, we showed that patients with IDH-nonmutated tumors were significantly older (P P6cm, PP) and were almost all p53 negative with no 1p19q deletion (P -6). Conclusions: The combined absence of IDH mutations, p53 expression and 1p19 codeletion in LGGs identifies a novel entity coined “Triple negative” tumors with distinctive location, infiltrative behavior, specific molecular alterations and dismal outcome. These findings could significantly modify LGG classification and may represent a new tool to guide patient-tailored therapy.


  • Une cause rare de défaillance cardiaque brutale chez le nourrisson : la cardiomyopathie histiocytoïde

    by Béma Coulibaly, Marie-Dominique Piercecchi-Marti, Carla Fernandez, Anne-Pascale Wasier, Laurent Viard, Alain Fraisse, Dominique Figarella-Branger, Georges Leonetti, Jean Camboulives, Olivier Paut


  • Un mélanocytome mimant un adénome hypophysaire

    by Béma Coulibaly, Corinne Bouvier, André Maues de Paula, Carla Fernandez, Henry Dufour, Dominique Figarella-Branger


  • Epidermal growth factor receptor in glioblastomas: correlation between gene copy number and protein expression

    by Béma Coulibaly, Isabelle Nanni, Benoit Quilichini, Jean Gaudart, Philippe Metellus, Frédéric Fina, Céline Boucard, Olivier Chinot, L'Houcine Ouafik, Dominique Figarella-Branger


  • Prognostic impact of stem cell marker CD133 in 61 glioblastoma patients treated with concomitant chemoradiation: A prospective study.

    by P. Metellus, I. Nanni-Metellus, C. Delfino, C. Colin, B. Coulibaly, F. Fina, O. L. Chinot, D. Figarella-Branger, L. Ouafik

    2027 Background: Cancer stem cells (CSC) are thought to represent the population of tumorigenic cells responsible for tumor development. The CD133 antigen has been described as a putative stem cell marker in malignant brain tumor that could identify such a tumorogenic population in a subset of glioblastoma multiforme (GBM). To date, the correlation between CD133 expression in primary GBM and patients' prognosis is not clearly established. To address this question we investigated the relationship between the expression of CD133 marker and glioblastoma patients outcome. Methods: The quantittative expression of CD133 stem cell antigen mRNA was assesszed using real-tima quantitative RT-PCR in a prospective cohort of 61 primary GBM patients treated with radiotherapy combined with concomitant and adjuvant therapy with temozolomide. Results: On multivariate survival analysis, CD133 stem cell antigen expression was a significant (p = 0.007) prognostic factor for adverse overall survival independent of extent of resection (p = 0.012), patient age (p = 0.037) and MGMT status (p = 0.002). Furthermore, according to the conjoined expression of CD 133 and MGMT status, the patients were categorized into three groups. Among these three groups, patients with methylated tumors and low expression level of CD 133 (group I) had the best prognosis, patients with unmethylated tumors and high expression level of CD 133 (group III) had the poorest prognosis and others (group II) had an intermediate outcome. Conclusions: These findings constitute conclusive evidence that the measurement of the mRNA expression of CD133 stem cell antigen carried by some GBM cancer stem cells actually impact the survival of GBM patients, lending support to the current brain tumor stem cell hypothesis. No significant financial relationships to disclose.


  • Lethal injection of potassium chloride: first description of the pathological appearance of organs

    by Béma Coulibaly, Marie‐Dominique Piercecchi‐Marti, Christophe Bartoli, Agnes Liprandi, Georges Léonetti, Jean‐François Pellissier

    Lethal injection of potassium chloride (KCl) can be used as a method of either suicide or homicide. As biological tests are still inadequate to differentiate endogenous from exogenous potassium, at the scene of death the cause can only be suspected. We wished to determine the usefulness of conventional pathological examination in this context and carried out a study in four fetuses after medical termination of pregnancy for serious disease. Pregnancy was terminated by KCl injection in two cases and by injection of lidocaine and sufentanil in the other two cases. In each of the two fetuses in which KCl injection was performed, macroscopic examination showed whitish deposits on the tissues and histological examination showed clumps of lanceolate crystals in the internal organs. In the two fetuses which received lidocaine and sufentanil injection, no deposits were visible on macroscopic examination and no crystals were seen on histological examination. These findings suggest that pathological study may have useful applications in forensic medicine when death by potassium injection is suspected. Copyright © 2009 John Wiley & Sons, Ltd.


  • Open Access

    Recurrent dedifferentiated liposarcoma of mediastinum involving lung and pleura

    by Bema Coulibaly, Corinne Bouvier, Marie Jose Payan, Pascal Thomas

    We report a case of primary recurrent mediastinal dedifferentiated liposarcoma with unusual long-term survival. A woman who complained of dyspnea showed on imaging features a bulky posterior mediastinal mass which was completely excised and initially misdiagnosed as an angiomyolipoma. She recurred 15 months later and histological examination showed a dedifferentiated liposarcoma. Resection was incomplete and the patient received adjuvant therapy. Eight years later a second recurrence occurred in the right pleura and lung. The patient died three months later.